Website
News25/Ratings12
News · 26 weeks82-48%
2025-10-262026-04-19
Mix5690d
- Insider29(52%)
- SEC Filings13(23%)
- Other9(16%)
- Earnings2(4%)
- Dividends1(2%)
- M&A1(2%)
- Other1(2%)
Latest news
25 items- ANALYSTAbbott Labs downgraded by Daiwa Securities with a new price targetDaiwa Securities downgraded Abbott Labs from Outperform to Neutral and set a new price target of $92.00
- SECAbbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRNew data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection TestData show how a multi-biomarker class approach improves early-stage cancer detectionAACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCEDABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard® test. Additionally, the AACR Cancer Prevention Research Award for Outstanding Journal Article will recognize a publication on MCED multiyear outcomes from the DETECT-A
- SECAbbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact SciencesFirst-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percentCompleted acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics marketAbbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact SciencesABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE:ABT) announced financial results for the first quarter ended March 31, 2026. First-quarter sales increased 7.8 percent on a reported basis and 3.7 percent on a comparable basis.First-quarter GA
- PRNew survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their healthWith chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthyABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE:ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health. In the U.S. alone, three in four American adults have at least one chronic condition1. With chronic disease continually on the rise2
- INSIDERSEC Form 4 filed by Stratton John G4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Roman Michael F4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Gonzalez Patricia Paola4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Alpern Robert J4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 4 filed by Ahuja Nita4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- PRAbbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platformBroadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment decisionsAllows oncologists to order tests and view results directly in the clinical workflowABBOTT PARK, Ill. and NEW YORK, March 30, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott's comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron's cloud-based Electronic Medical Record (EMR) platform. Through this integration, onc
- PRAbbott hosts conference call for first-quarter earningsABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.About Abbott: Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical
- INSIDERSEC Form 4 filed by Orville Jacob A4 - ABBOTT LABORATORIES (0000001800) (Issuer)
- INSIDERSEC Form 3 filed by new insider Orville Jacob A3 - ABBOTT LABORATORIES (0000001800) (Issuer)
- PRJohn Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screeningPotentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+Learn more at Cologuard.com/TheTalkABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced a new campaign encouraging people to stop avoiding awkward conversations about colorectal cancer. The company is reuniting beloved sitcom family members, John Stamos and Jodie Sweetin, for "The (Second) Talk" campaign – because when it comes to colon cancer screening, even adults need another trusted adult for advice."The (Second) Talk," brings back TV's favorite uncle and niece duo to spoof "the talk" for a nostalgic, sitcom-style skit to remind people that while colon ca
- SECSEC Form S-8 filed by Abbott LaboratoriesS-8 - ABBOTT LABORATORIES (0000001800) (Filer)
- SECAbbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ABBOTT LABORATORIES (0000001800) (Filer)
- PRAbbott completes acquisition of Exact SciencesEstablishes Abbott as a leader in fast-growing cancer screening and diagnostics segmentsAdvances Abbott's mission to make healthcare more accessible and give people more control over their healthABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. "Abbott's global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized trea
- PRAbbott acquisition of Exact Sciences set to close on March 23, 2026Announcement follows receipt of all regulatory clearances necessary for closingTransaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional peopleABBOTT PARK, Ill., March 20, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) today announced that it expects to close the acquisition of Exact Sciences on Monday, March 23, 2026. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions of additional people. Together with Exact Sciences, Abbott will accelerate innovation, expand access
- SECSEC Form DEFA14A filed by Abbott LaboratoriesDEFA14A - ABBOTT LABORATORIES (0000001800) (Filer)
- SECSEC Form DEF 14A filed by Abbott LaboratoriesDEF 14A - ABBOTT LABORATORIES (0000001800) (Filer)
- PRLandmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose managementU.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2Improvements were participant-led, using real-time glucose readings to guide everyday decisionsComplementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population3ABBOTT PARK, Ill., March 12, 2026 /PRNewswire/ -- Abbott (NYSE:ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes tha
- PRAbbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team'Abbott, in collaboration with Real Madrid, will host free selection events combining soccer and health education to identify the second annual 'Abbott Dream Team'All participants will receive sports nutrition guidance from Abbott experts and take part in on-field development sessions led by Real Madrid coachesThe 16 selected male and female 'Abbott Dream Team' members, ages 18–19, will travel to Spain on an all‑expenses‑paid trip to train at Real Madrid's official facilitiesLearn more and register at AbbottDreamTeam.comABBOTT PARK, Ill., March 11, 2026 /PRNewswire/ -- Abbott (NYSE:ABT) announced today the launch of the second year of the 'Abbott Dream Team,' encouraging young soccer players
- SECAbbott Laboratories filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - ABBOTT LABORATORIES (0000001800) (Filer)